Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented ...

Ipsen announces Bylvay data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS: Paris, France Tuesday, November 19, 2024, 11:00 H ...

Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

There are dermatologists who don’t have much training in vulvar dermatology, and a lot of gyns don’t get as much training” as ...

In addition, data from the Phase 2 study evaluating MRGPRX4 in cholestatic pruritus, CP, does not support further development.” Don't Miss our Black Friday Offers: Published first on TheFly – the ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte (INCY – Research Report) today and set a price target of $69.00.Don't ...

WILMINGTON, Del., November 18, 2024 -- ( BUSINESS WIRE )--Incyte (Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) shares fell 4.6% on Monday after an insider sold shares in the company. The stock traded as low as $41.93 and last traded at $42.47. 48,697 ...